AU2014386214B2 - Methods and reagents for radiolabeling - Google Patents

Methods and reagents for radiolabeling Download PDF

Info

Publication number
AU2014386214B2
AU2014386214B2 AU2014386214A AU2014386214A AU2014386214B2 AU 2014386214 B2 AU2014386214 B2 AU 2014386214B2 AU 2014386214 A AU2014386214 A AU 2014386214A AU 2014386214 A AU2014386214 A AU 2014386214A AU 2014386214 B2 AU2014386214 B2 AU 2014386214B2
Authority
AU
Australia
Prior art keywords
nitrogen
sulfur
oxygen
compound
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014386214A
Other languages
English (en)
Other versions
AU2014386214A1 (en
Inventor
Gabriela Chiosis
Stefan O. OCHIANA
Nagavarakishore Pillarsetty
Tony Taldone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2014386214A1 publication Critical patent/AU2014386214A1/en
Application granted granted Critical
Publication of AU2014386214B2 publication Critical patent/AU2014386214B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2014386214A 2013-12-23 2014-12-23 Methods and reagents for radiolabeling Ceased AU2014386214B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361919901P 2013-12-23 2013-12-23
US61/919,901 2013-12-23
PCT/US2014/072090 WO2015138039A1 (en) 2013-12-23 2014-12-23 Methods and reagents for radiolabeling

Publications (2)

Publication Number Publication Date
AU2014386214A1 AU2014386214A1 (en) 2016-07-14
AU2014386214B2 true AU2014386214B2 (en) 2020-05-21

Family

ID=54072256

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014386214A Ceased AU2014386214B2 (en) 2013-12-23 2014-12-23 Methods and reagents for radiolabeling

Country Status (13)

Country Link
US (3) US9994573B2 (enExample)
EP (1) EP3086792B1 (enExample)
JP (1) JP6491214B2 (enExample)
KR (1) KR102325454B1 (enExample)
CN (1) CN106456645B (enExample)
AU (1) AU2014386214B2 (enExample)
BR (1) BR112016014758A8 (enExample)
CA (1) CA2934850C (enExample)
IL (1) IL246403B (enExample)
MX (1) MX2016008418A (enExample)
RU (1) RU2016128528A (enExample)
TW (1) TWI673279B (enExample)
WO (1) WO2015138039A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138039A1 (en) 2013-12-23 2015-09-17 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
MX387627B (es) * 2014-09-17 2025-03-18 Memorial Sloan Kettering Cancer Center Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia
WO2017002196A1 (ja) * 2015-06-30 2017-01-05 株式会社日立国際電気 整合器及び整合方法
KR102175125B1 (ko) * 2018-12-28 2020-11-05 울산과학기술원 미토콘드리아 표적 Hsp90 억제제 기반 화합물 및 이를 포함하는 광역학 치료를 위한 약학적 조성물
WO2022182731A1 (en) * 2021-02-24 2022-09-01 Samus Therapeutics, Inc. Sn-labeling and radiolabeling of epichaperome inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084030A2 (en) * 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
WO2012138894A1 (en) * 2011-04-05 2012-10-11 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
WO2013009657A1 (en) * 2011-07-08 2013-01-17 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
WO2014144715A1 (en) * 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
WO2015023976A2 (en) * 2013-08-16 2015-02-19 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US20070178537A1 (en) * 2003-06-30 2007-08-02 Sloan-Kettering Institute For Cancer Research Assays for detection of bioactive compounds that interact with heat shock protein 90
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2007134298A2 (en) 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
WO2008005937A2 (en) 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
KR101313804B1 (ko) 2007-03-20 2013-10-01 쿠리스 인코퍼레이션 Ｈｓｐ９０ 억제제로서의 융합된 아미노 피리딘
NZ586129A (en) 2007-11-14 2012-06-29 Myrexis Inc Therapeutic compounds and their use in treating diseases and disorders
JP5941407B2 (ja) 2009-10-07 2016-06-29 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害剤
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
BR112013027448A2 (pt) 2011-04-28 2020-09-01 Sloan-Kettering Institute For Cancer Research terapia de combinação com hsp90
WO2015138039A1 (en) 2013-12-23 2015-09-17 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
MX387627B (es) 2014-09-17 2025-03-18 Memorial Sloan Kettering Cancer Center Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia
US20180280397A1 (en) 2015-10-05 2018-10-04 Memorial Sloan Kettering Cancer Center Rational combination therapy for the treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084030A2 (en) * 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
WO2012138894A1 (en) * 2011-04-05 2012-10-11 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
WO2013009657A1 (en) * 2011-07-08 2013-01-17 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
WO2014144715A1 (en) * 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
WO2015023976A2 (en) * 2013-08-16 2015-02-19 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof

Also Published As

Publication number Publication date
EP3086792B1 (en) 2022-10-12
CA2934850C (en) 2022-12-06
BR112016014758A8 (pt) 2020-06-02
US20200017502A1 (en) 2020-01-16
IL246403B (en) 2020-08-31
US20170029426A1 (en) 2017-02-02
TWI673279B (zh) 2019-10-01
RU2016128528A (ru) 2018-01-30
BR112016014758A2 (enExample) 2017-08-08
JP6491214B2 (ja) 2019-03-27
EP3086792A4 (en) 2017-05-24
US20180251461A1 (en) 2018-09-06
MX2016008418A (es) 2017-01-11
CN106456645A (zh) 2017-02-22
AU2014386214A1 (en) 2016-07-14
WO2015138039A1 (en) 2015-09-17
EP3086792A1 (en) 2016-11-02
CN106456645B (zh) 2021-03-23
KR102325454B1 (ko) 2021-11-16
US9994573B2 (en) 2018-06-12
CA2934850A1 (en) 2015-09-17
US10329293B2 (en) 2019-06-25
KR20160101186A (ko) 2016-08-24
US10793570B2 (en) 2020-10-06
IL246403A0 (en) 2016-08-31
TW201609773A (zh) 2016-03-16
JP2017502039A (ja) 2017-01-19

Similar Documents

Publication Publication Date Title
US10793570B2 (en) Methods and reagents for radiolabeling
CN115175908A (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN113666923A (zh) 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
JP2022549171A (ja) 縮合ピリドン化合物、ならびにその調製方法および使用
JP2025528779A (ja) Ｐｄｅ４ｂ阻害剤及びその用途
CN107106559A (zh) 自分泌运动因子的取代的螺环抑制剂
EA020885B1 (ru) Ингибиторы протеинкиназы и их применение
WO2011050284A1 (en) Pyrazolylpyridine antiviral agents
JP7029444B2 (ja) Ｐｄｅ４阻害剤
AU2020401999B2 (en) Compound as cyclin-dependent kinase 9 inhibitor and use thereof
EP3774755B1 (en) Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase
JP7417519B2 (ja) チエノジアゼピン誘導体とその応用
KR20250054814A (ko) Cdk4 키나아제 억제제로 사용되는 화합물 및 이의 용도
WO2022018072A1 (en) Tricyclic heterocycles
CN113698415A (zh) 一种新型的冬凌草甲素类似物及衍生物、其制备方法及医药用途
HK40105472A (zh) 用作cdk4激酶抑制剂的化合物及其应用
JP3068175B2 (ja) イソチアゾロ〔５，４―ｂ〕ピリジン誘導体
CN110903289A (zh) 嘌呤-氨甲基-吡啶酮衍生物及其制备方法和用途
WO2024243449A1 (en) Rapamycin derivatives and uses thereof
CA3285927A1 (en) Kif18a inhibitor
CN104557844B (zh) 一种独一味素a的衍生物、制备方法及应用
CN121293164A (zh) 一种小分子化合物及其制备方法与在抗癌药物中的应用
CN113461700A (zh) 一种氧气促进的去芳香化反应在构建螺环二烯酮骨架中的应用
CN113214298A (zh) 一种硼酸酯类化合物及其应用
FR2757859A1 (fr) Nouveaux derives d'ellipticine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired